The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Dovitinib as second-line therapy in patients with fibroblast growth factor receptor 2 (FGFR2)-mutated or non-mutated advanced and/or metastatic endometrial cancer (EC): A single-arm, multicenter, phase II study.
Gottfried E. Konecny
No relevant relationships to disclose
Neil Finkler
No relevant relationships to disclose
Agustin Garcia
Consultant or Advisory Role - Novartis
Francesco Raspagliesi
No relevant relationships to disclose
Carolina Muriel Lopez
No relevant relationships to disclose
Michael McCollum
No relevant relationships to disclose
M Jesus Rubio
No relevant relationships to disclose
Matthew Squires
Employment or Leadership Position - Novartis
Nicoletta Pirotta
Employment or Leadership Position - Novartis
Allison Upalawanna
No relevant relationships to disclose
Alejandro Javier Yovine
Employment or Leadership Position - Novartis
Rodney Paul Rocconi
No relevant relationships to disclose